Skip to main content
  • Maximize development ROI with integrated local and global solutions

  • NMPA GLP-certified facility

  • Consistent, high quality data through global SOPs, platforms and standards across central laboratories

As one of the world’s largest drug development companies, we can deliver integrated, in-country solutions. 

Solutions in China

At Labcorp, we work as your resourceful partner to provide innovative solutions, share unique perspectives and deliver quality results. Learn more about how you can save time and experience new cost efficiencies by accessing our integrated solutions. 

Nonclinical Development: Our dedicated NMPA GLP certified facility in Shanghai, China features a number of accreditations to fulfill global quality standards (FDA, OECD, etc.). Teaming up with global resources and partners in China, we offer solutions for a full range of safety assessments needed by IND filing and FIH. Specific solutions for small molecules and biologics include:

Clinical testing - Central Laboratory Services: Receive consistent and high-quality data through our globally standardized methods and processes. Operating since 2007, our Shanghai site offers:

  • Core Laboratory Testing services:
    • Genomics services
    • Special Chemistry
    • Immunochemistry
    • Hematology
    • Flow Cytometry
    • Specimen Management and Biorepository
    • Safety Testing
  • Anatomic Pathology
  • Biomarker Services
  • Scientific Consultation
  • Data Management
  • Project Management
  • Investigator Site Support
  • Global Logistics

Local expertise

Partner with our network of regulatory experts, solution directors and program managers to meet your needs in regulatory filling both in China and globally. With accumulated experience, we provide insights to help you reach decision points faster. 

  • Regulatory support: Approval times in China are among the longest in the world. Get experienced consulting with your product development plan and regulatory submissions from our regulatory personnel who have years of product development experience and proactively stay abreast of the latest regulatory changes. Register your compound in the U.S., European and the rest of the world with the support of our skilled regulatory staff who have extensive experience interacting with NMPA, FDA, EMA and other Health Authorities globally.
  • Program management: Gain insight and support from our program management team to proactively reveal opportunities for your molecule.
  • In-country expertise: leverage our scientific, regulatory and operational expertise across the development continuum for informed insights that deliver decision driving data.

With a powerful economy, large population and strong talent pool, China is quickly becoming a leading region for R&D. Consider other factors in China’s drug development and clinical trial landscape:

  • Extensive growth: Viewed as a key emerging market for multinational pharmaceutical companies with an increase in clinical trials activity, China is expected to become a leading pharmaceutical consumer in the next few years.
  • Accessible patients: China holds great potential to reach a large number of treatment-naïve patients, a growing elderly population and diverse ethnic groups in a relatively low-cost environment. 

Locations

Whether supporting a global trial in China, bringing a product into China or introducing a domestic product to the Western markets, we are ready to deliver your results.

Enquiries

Tel: +86 21 6192 5800
Fax: +86 21 6192 5900

Office Address:

Labcorp Drug Development Pharmaceutical Research and Development (Shanghai) Co., Ltd.
Building #3, No. 3377 Kangxin Rd.
SIMZ Pudong
Shanghai 201318, China

Labcorp Drug Development Pharmaceutical Research and Development (Shanghai) Co. Ltd.
Beijing Branch
Room 1818, Floor 18, Building 7
No. 6 Jiuxianqiao Road
Chaoyang District, Beijing 100015, China

Labcorp Drug Development Pharmaceutical Research and
Development (Shanghai) Co., Ltd.
No. 9 Building, No. 338 Jialilue Road
Zhangjiang Hi-Tech Park, Shanghai 201201, China

Let's start a conversation